• Eftychia A Demerouti, Athanassios N Manginas, George D Athanassopoulos, George T Karatasakis, Evangelos D Leontiadis, and Gregory S Pavlides.
• Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece. efidemer@otenet.gr
• Respir Care. 2013 Feb 1;58(2):e1-5.

AbstractPulmonary arterial hypertension is a rare and devastating disease characterized by vascular proliferation and remodeling. Epoprostenol, the drug counterpart of the eicosanoid prostacyclin, produced by the vascular endothelial cells, is the drug of choice for this disease. Its capacity to act rapidly and to significantly improve survival prospects in severe pulmonary hypertension patients has been supported by a wealth of evidence. Intravenous epoprostenol was believed to require therapy of indefinite duration. Since 2001, oral drugs have been approved for specific treatment. The availability of newer and less invasive drug therapies for pulmonary arterial hypertension led physicians to withdraw epoprostenol in carefully selected patients. We report a case of successful intravenous epoprostenol interruption in a patient with idiopathic disease. A literature review on epoprostenol withdrawal in pulmonary hypertension in adult patients is also provided.© 2013 Daedalus Enterprises.

28 keywords...

hide…